Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353664 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01353664 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 19 participants.
The verdict
NCT01353664, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.
Interventions
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-05-01 |
| Est. Completion | 2012-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353664
The ClinicalTrials.gov registry entry for NCT01353664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romidepsin is the first listed.
NCT01353664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353664 about?
NCT01353664 is a clinical study titled "A Rollover Study for Patients Who Participated in Other Romidepsin Protocols". This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.
What is the current status of trial NCT01353664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-05-01. Estimated completion is 2012-09-05.
What interventions are being tested in trial NCT01353664?
The interventions under investigation include: Romidepsin (DRUG).
Who is sponsoring clinical trial NCT01353664?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.